1. Home
  2. AHG vs ANAB Comparison

AHG vs ANAB Comparison

Compare AHG & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AHG
  • ANAB
  • Stock Information
  • Founded
  • AHG 2013
  • ANAB 2005
  • Country
  • AHG China
  • ANAB United States
  • Employees
  • AHG N/A
  • ANAB N/A
  • Industry
  • AHG Business Services
  • ANAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • AHG Consumer Discretionary
  • ANAB Health Care
  • Exchange
  • AHG Nasdaq
  • ANAB Nasdaq
  • Market Cap
  • AHG 765.9M
  • ANAB 621.1M
  • IPO Year
  • AHG N/A
  • ANAB 2017
  • Fundamental
  • Price
  • AHG $1.78
  • ANAB $20.22
  • Analyst Decision
  • AHG
  • ANAB Buy
  • Analyst Count
  • AHG 0
  • ANAB 10
  • Target Price
  • AHG N/A
  • ANAB $48.00
  • AVG Volume (30 Days)
  • AHG 34.0K
  • ANAB 459.5K
  • Earning Date
  • AHG 09-02-2025
  • ANAB 08-06-2025
  • Dividend Yield
  • AHG N/A
  • ANAB N/A
  • EPS Growth
  • AHG N/A
  • ANAB N/A
  • EPS
  • AHG N/A
  • ANAB N/A
  • Revenue
  • AHG $14,777,798.00
  • ANAB $123,164,000.00
  • Revenue This Year
  • AHG N/A
  • ANAB N/A
  • Revenue Next Year
  • AHG N/A
  • ANAB $24.39
  • P/E Ratio
  • AHG N/A
  • ANAB N/A
  • Revenue Growth
  • AHG 512.09
  • ANAB 304.17
  • 52 Week Low
  • AHG $0.74
  • ANAB $12.21
  • 52 Week High
  • AHG $2.35
  • ANAB $40.70
  • Technical
  • Relative Strength Index (RSI)
  • AHG 52.90
  • ANAB 34.66
  • Support Level
  • AHG $1.63
  • ANAB $19.48
  • Resistance Level
  • AHG $1.84
  • ANAB $20.35
  • Average True Range (ATR)
  • AHG 0.12
  • ANAB 1.27
  • MACD
  • AHG -0.01
  • ANAB -0.13
  • Stochastic Oscillator
  • AHG 63.68
  • ANAB 18.49

About AHG Akso Health Group ADS

Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: